Abstracts tagged "Infection"

Abstract Number: 2577 • ACR Convergence 2025
Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
Liya Sisay Getachew¹, Xiaosong Wang², Zachary Wallace³, Naomi Patel⁴, Lauren O'Keeffe⁵, Madison Negron⁶, Grace Qian⁵, Alene Saavedra⁵, Kevin Mueller⁵, Natalie Davis⁷, Yijia Li⁸, Manish Choudhary⁵, Julie Boucau³, Brooke Leeman⁵, Gregory Edelstein⁵, Owen Glover³, Yumeko Kawano⁵, Rinki Deo⁵, Caitlin Marino³, Zahra Reynolds³, Karry Su³, Chase Mandell³, Eliza Passell³, Mamadou Barry³, Andrew Alexandrescu³, Dibya Ghimire³, Mriganka Mandal⁹, Tammy Vyas³, Sarah Hammond³, Jatin Vyas³, Jacob Lemieux³, Mark Siedner³, Amy Barczak³, Jonathan Li³ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Natick, MA, ³Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, ⁶Harvard Extension School, Medford, MA, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸University of Pittsburgh, Pittsburgh, ⁹Dana-Farber Cancer Institute, Boston
Background/Purpose: People with rheumatic diseases are at risk for acute and post-acute COVID-19 outcomes in part due to immunosuppressive medications. Those on B-cell depleting therapies…
Abstract Number: 1621 • ACR Convergence 2025
Temporal Association Between Viral Positivity Rates and Kawasaki Disease Incidence at a Large Tertiary Center
Jessica Nguyen¹, Duc Nguyen¹, Ankona Banerjee², Kenneth Nobleza², Denver Niles² and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis associated with the development of coronary artery aneurysms predominantly affecting children less than 5 years of age.…
Abstract Number: 0609 • ACR Convergence 2025
Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
Eleni Papachristodoulou¹ and Vasileios Kyttaris², ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Neutropenia is a known hematologic manifestation of SLE, yet its clinical implications remain poorly defined. We conducted a retrospective study to characterize the frequency,…
Abstract Number: 0585 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
Shikha Singla¹, Linda Grinnell-Merrick², Weibin Bao³, Artem Zharkov⁴ and Abhijeet Danve⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic disease characterized by inflammatory low back pain and is often accompanied by inflammation of the peripheral joints and…
Abstract Number: 2575 • ACR Convergence 2025
Influenza and COVID-19 Vaccination Uptake Among Women with Systemic Rheumatic Diseases in New York City Assessed Between 2022 and 2024
Yongjay Kim¹, Sandhya Kannayiram², Amaya Smole³, Lucy Masto⁴, Neha Nagpal⁵, Naiva Manuela Piatchou Donfack⁵, Deanna Jannat-Khah⁵, Lisa Mandl⁵, Caroline Siegel⁵, Sarah Lieber⁵, Michael Lockshin⁵, Lisa Sammaritano⁵ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, Englewood Cliffs, NJ, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, ³Hospital for Special Surgery, Brooklyn, NY, ⁴Hospital for Special Surgery, San Francisco, CA, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Women with systemic rheumatic diseases (SRDs), and particularly those on immunosuppressive medications, are at increased risk for serious infections such as influenza and COVID-19.…
Abstract Number: 1607 • ACR Convergence 2025
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Natasha Le Blanc¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Nataliya Milman⁹, Medha Soowamber¹⁰, Nader Khalidi¹¹, Christian Pagnoux¹⁰, Rosalie-Selene Meunier¹², Jan Willem Cohen Tervaert⁴, Elaine Yacyshyn⁴ and Arielle Mendel¹³, ¹McGill University, Montreal, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Self employed, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Universite de Montreal, Montreal, Canada, ⁹the Ottawa Hospital, Ottawa, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Hopital du Sacre-Coeur-de-Montreal, Montreal, QC, Canada, ¹³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Antibiotic prophylaxis is recommended during initial treatment of ANCA-associated vasculitis (AAV). We assessed characteristics associated with prophylaxis within a Canadian multicenter AAV cohort starting…
Abstract Number: 0606 • ACR Convergence 2025
Increased Recombinant Zoster Vaccination in SLE following Public Reimbursement: Data from Two Prospective SLE Cohorts
Arielle Mendel¹, Nathalie Amiable², Yvan St-Pierre³, Sasha Bernatsky⁴, Ines Colmegna⁵, Michaël Desjardins⁶, Louis-Pierre Grenier⁷, Fares Kalache⁸, Christian Pineau⁹, Chantal Sauvageau¹⁰, Evelyne Vinet⁴ and Paul Fortin¹¹, ¹McGill University Health Centre, Montréal, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Centre Hospitalier de l'Université de Montréal (CHUM)), Montreal, QC, Canada, ⁷Montreal General Hospital, Montréal, QC, Canada, ⁸McGill University Health Center, Montreal, QC, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Institut national de santé publique du Québec, Quebec City, QC, Canada, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Herpes Zoster (shingles) is a common preventable adverse event in SLE. In Quebec, Canada, the Recombinant Zoster Vaccine (RZV) became free of charge for…
Abstract Number: 2574 • ACR Convergence 2025
Differences in SARS-CoV-2 Antigen Persistence in Individuals with Systemic Autoimmune Rheumatic Diseases Compared to the General Population
Naomi Patel¹, Zoe Swank², Jiaqi Wang¹, Xiaosong Wang³, Lauren O'Keeffe², Madison Negron⁴, Liya Sisay Getachew⁵, Louise Hansen⁶, Grace Qian², Alene Saavedra², Kevin Mueller², Natalie Davis⁷, Kathleen Vanni⁵, Zachary Wallace⁸, David Walt² and Jeffrey Sparks⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Harvard Extension School, Medford, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, B, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post-acute COVID-19 outcomes due to use of immunosuppressive medications and…
Abstract Number: 1540 • ACR Convergence 2025
Association of Hypoalbuminemia with Serious Infections in Systemic Lupus Erythematosus Patients Receiving Dialysis
Ping Hsuan Kuo¹, Pu Jun Fang², Chien-Chih Lai³ and Yi-Syuan Sun⁴, ¹Taipei Veteran General Hospital, Taipei City, Taiwan (Republic of China), ²Tri-Service General Hospital, Hukou Township, Taiwan (Republic of China), ³Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ⁴taipei VGHTPE, ???, Taiwan (Republic of China)
Background/Purpose: Lupus nephritis, a key manifestation of systemic lupus erythematosus (SLE), can progress to end-stage kidney disease and increase patient burden. While patients with SLE…
Abstract Number: 0806 • ACR Convergence 2025
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Teng-Chieh Hsu¹, An-Ping Huo², Pei-Lun Liao², Pui-Ying Leong² and James Wei³, ¹Wuri Lin Shin Hospital, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China)
Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…
Abstract Number: 2573 • ACR Convergence 2025
Impaired Humoral Response to Recombinant Herpes Zoster Vaccine in Rituximab Treated Autoimmune Rheumatic Diseases Patients: A Prospective Controlled Phase 4 Study
Nadia Emi Aikawa¹, Henrique Dalmolin², Sandra G Pasoto³, Ana C Medeiros-Ribeiro³, Luciana Parente Costa Seguro⁴, Emily Figueiredo Neves Yuki⁵, Carlos Emilio Insfran Echauri³, Clovis Artur Silva⁶ and Eloisa Bonfa⁴, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ²Santa Casa de Sao Paulo and Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁵Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁶University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at increased risk for herpes zoster (HZ), especially those treated with B-cell depleting agents. Although the recombinant…
Abstract Number: 1475 • ACR Convergence 2025
Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus
Arielle Mendel¹, Maximilien Lora², Sasha Bernatsky³, Paul Fortin⁴, Michaël Desjardins⁵, Joyce Rauch⁶, Chantal Sauvageau⁷, Evelyne Vinet³ and Ines Colmegna⁸, ¹McGill University Health Centre, Montreal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁵Centre Hospitalier de l'Université de Montréal (CHUM)), Montreal, QC, Canada, ⁶McGill University, Hampstead, Canada, ⁷Institut national de santé publique du Québec, Quebec City, QC, Canada, ⁸The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for herpes zoster (HZ) and its complications. Exposure to immunosuppressants (IS) at the time…
Abstract Number: 0490 • ACR Convergence 2025
Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis
Li Liu¹, Xue-Mei Zhang¹, Zhi-Chun Gu¹ and Jia Li², ¹Ren Ji Hospital, Shanghai Jiao Tong University School Of Medicine, Pu Dong Xin Qu, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: This study aimed to evaluate the infection risks in patients with rheumatoid arthritis (RA) treated with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),…
Abstract Number: 2526 • ACR Convergence 2025
Infection Risk Associated with Steroid-Sparing Therapies in GCA, PMR, and ANCA-Associated Vasculitis: A Systematic Review
Divya Sudireddy¹, Brent Leung², Jean Liew³, Tuhina Neogi⁴, David Felson³, Michael LaValley⁵ and David Flynn², ¹Boston Medical Center, Westborough, MA, ²Boston University, Boston, ³Boston University, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA
Background/Purpose: Giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and ANCA-associated vasculitis (AAV) often require long-term glucocorticoid (GC) therapy, increasing the risk of infections, particularly in…
Abstract Number: 1459 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
Shikha Singla¹, Linda Grinnell-Merrick², Weibin Bao³, Artem Zharkov⁴ and Abhijeet Danve⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: PsA is a chronic inflammatory disease characterized by joint pain, swelling and stiffness, and is often accompanied by cutaneous changes linked to psoriasis. Patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].